Franssen AM

No ORCID on file · 5 papers in corpus · active 1986-1992

Study types

  • article 4
  • rct 1

Condition tags

  • endometriosis 5
  • dysmenorrhea 1
rct 1992
On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol
Fertility and Sterility ·doi:10.1016/s0015-0282(16)55011-0

OBJECTIVE: To further elucidate the origin and significance of serum CA-125 in pelvic endometriosis. DESIGN: Retrospective. PATIENTS: Ninety-seven women with endometriosis who participated in two trials: (1) open-label study on buserelin …

article 1989
Endometriosis: treatment with gonadotropin-releasing hormone agonist Buserelin
Fertility and Sterility ·doi:10.1016/s0015-0282(16)60544-7

Fifty-one women with pelvic endometriosis were treated with the gonadotropin-releasing hormone agonist (GnRHa) Buserelin (Hoechst Holland N.V., Amsterdam, The Netherlands) 300 micrograms three times a day intranasally for 6 months. Forty-ni…

article 1986
Round table discussion of endometriosis and its treatment.
Progress in clinical and biological research
article 1986
The effect of LHRH agonist therapy in the treatment of endometriosis (Dutch experience).
Progress in clinical and biological research
article 1986
Treatment with a luteinising hormone-releasing hormone analogue (Buserelin) in danazol-resistant endometriosis patients
European journal of obstetrics, gynecology, and reproductive biology ·doi:10.1016/0028-2243(86)90173-5

Luteinising hormone-releasing hormone agonist (Buserelin) therapy administered for a period of 6 months in 4 patients with longstanding, severe, danazol-resistant endometriosis, was found to be effective in reducing all complaints related t…